Merck completes $10B acquisition of Verona Pharma, adding Ohtuvayre — the first new inhaled COPD therapy in over 20 years.
Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a study titled ‘A Phase 2b/3, Randomized, ...
Telemedicine significantly improved quality of life and inhaler technique in advanced COPD patients compared to traditional ...
If you start to experience symptoms like chest pain, blue lips, or coughing up more than a teaspoon of blood, you should see ...
Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...
Scientists at UCSF identified a key cellular switch that plays a large role in pulmonary fibrosis, and found a way of ...
Tivardi Therapeutics (NASDAQ:TVRD) is down ~85% in Monday trading after reporting that preliminary results from a phase 2 ...
Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white blood ...
Respiratory diseases such as Asthma and Chronic Obstructive Pulmonary Disease (COPD) are on the rise partly because of ...
After 1 year of biologic therapy, admissions requiring noninvasive ventilation among patients with COPD and type 2 ...
Jascayd targets the enzyme PDE4B, which plays a role in the inflammatory process. The new therapy is able to affect both ...
Recent medical research is reshaping our understanding of Chronic Obstructive Pulmonary Disease (COPD), particularly highlighting its disproportionate impact on women. This shift in the COPD landscape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback